

PATHFINDER

February 28, 2014

Steven D. Singleton
Limestone Fund, LLC
1600 Division Street, Suite 580
Nashville, TN 37203

Dear Mr. Singleton:

Pursuant to the Amendment to Series B3 Stock and Warrant Purchase Agreement entered into as of February 28, 2014, by and between Limestone Fund, LLC and Pathfinder Therapeutics, Inc., a Delaware Corporation, Limestone Fund, LLC, has purchased Series B3 Preferred Stock of Pathfinder Therapeutics, Inc. for \$25,000.

Thank you,



Jeffrey Terrell
Pathfinder VP, Corporate Development & Strategy